Advertisement
Document › Details
Medigene AG. (2/2/17). "Press Release: Medigene Participates at Five National and International Conferences in February and March 2017". Martinsried.
Medigene AG (FSE: MDG1, Prime Standard) announces its participation at five upcoming scientific, investor and business development conferences:
* Biotech and Money London
Date: 07 - 08 February 2017
Location: London, UK
Dr. Thomas Taapken, Medigene's CFO, will give a corporate presentation on 8th February at 9.25 am.
* ODDO 11th German Conference
Date: 15 - 16 February 2017
Location: Frankfurt, Germany
* International Symposium ACUTE LEUKEMIAS XVI
Date: 19 - 22 February 2017
Location: Munich, Germany
* 9th International Cellular Therapy Symposium
Date: 16 -17 March 2017
Location: Erlangen, Germany
* BIO-Europe Spring
Date: 20 - 23 March 2017
Location: Barcelona, Spain
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit http://medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
Record changed: 2023-06-05 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (11/21/23). "Press Release: Medigene AG Announces Prioritization of Pipeline and Resource Allocation as Well as Extension of Cash Runway". Planegg....
- [2] Medigene AG. (5/3/23). "Press Release: Medigene AG Reports Financial Results and Business Update for Q1 2023". Martinsried....
- [3] Medigene AG. (5/2/23). "Press Release: Medigene Acquires Worldwide, Exclusive License of CD40L-CD28 Costimulatory Switch Receptor". Planegg....
- [4] Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg....
- [5] Medigene AG. (1/18/23). "Press Release: Medigene Receives $3 Million Milestone Payment from 2seventy bio". Planegg....
- [6] Medigene AG. (2/25/22). "Press Release: Dr. Selwyn Ho Appointed New CEO of Medigene". Lisbon....
- [7] BioNTech SE. (2/21/22). "Press Release: BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer". Mainz & Martinsried....
- [8] Medigene AG. (1/28/21). "Press Release: Focus on Solid Tumors – Discontinuation of MDG1021 Development Program". Planegg-Martinsried....
- [9] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
- [10] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top